Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aripiprazole + escitalopram
- Development stage
- Phase 4
- Lead developer
- Otsuka Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral, Intramuscular
01
Overview
Aripiprazole + escitalopram is a combination of two pharmaceutical drugs used together, typically in the management of major depressive disorder (MDD) and other mood disorders when monotherapy with an antidepressant is insufficient. Aripiprazole is an atypical antipsychotic that acts as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors, and as an antagonist at serotonin 5-HT2A receptors. Escitalopram is a selective serotonin reuptake inhibitor (SSRI) that increases synaptic serotonin levels by inhibiting its reuptake into presynaptic neurons. The combination may enhance antidepressant efficacy through complementary mechanisms affecting both serotonergic and dopaminergic neurotransmission[2][4][7]. This regimen is not available as a fixed-dose commercial product but represents a common augmentation strategy in clinical psychiatry.
- Other names
- Aripiprazole/Escitalopram combinationAripiprazole/Escitalopram
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR2A (Serotonin receptor 5-HT2A)DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)SERT (Sodium-dependent serotonin transporter)
Beyond the preview
Go deeper on aripiprazole + escitalopram.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aripiprazole + escitalopram.